ALX Oncology Holdings Inc.
ALXO·NasdaqGS·Healthcare
1.2500+0.0700 (+5.93%)today
At close: Oct 9, 4:00 PM EDT · Real-time · USD
After hours1.2000−0.0500 (−4.00%)Oct 9, 6:24 PM EDT
Real-time prices from Yahoo Finance's public feed. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Previous close1.1800
Open1.1600
Day range1.15051.2900
52-week range1.05002.6600
Volume1.22M
Avg. volume (3M)1.05M
Market cap172.85M
P/E ratio (TTM)—
Forward P/E-2.32
EPS (TTM)-1.13
Dividend yield—
Beta (5Y)0.48
Shares outstanding138.28M
Earnings dateAug 6, 2026 (est.)
Analyst target4.6000
Profit margin0.00%
Latest news
All ALXO news ›ALX Oncology Announces Nature Medicine Publication of ASPEN-06 Phase 2 Clinical Data Demonstrating Strong Responses and Durable Clinical Benefit with Evorpacept in HER2-Positive Gastric Cancer
Achieved 40.3% ORR with evorpacept plus trastuzumab, ramucirumab and paclitaxel versus 26.6% for control, with response rates increasing to 63.6% versus 23.1% among patients with high CD47 expression and retained HER2-positive disease…
From articles in the 4Search news index.
In the news
2mentions in 30 days
2with it in the headline
Upbeatheadline tone
Mentioned with
People in the coverage
Themes
Most coverage from
-
finance.yahoo.com1
-
investing.com1
Measured across the 4ColoradoSprings news index. Headline tone is a simple word-based reading of the latest 2 headlines, not a forecast.